A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C

Maria Grazia Rumi, Elena Santagostino, M. Morfini, A. Gringeri, G. Tagariello, A. Chistolini, Patrizia Pontisso, A. Tagger, M. Colombo, P. M. Mannucci

Research output: Contribution to journalArticle

Abstract

There is limited information about the long-term efficacy of prolonged therapy (more than 6 months) with interferon in hemophilic patients with chronic hepatitis C who are not coinfected with the human immunodeficiency virus (HIV-1). One hundred and seven hemophiliacs were randomly assigned to 3 million U of interferon α2b three times weekly for 12 months or no therapy. The patients were followed up for at least 12 months posttreatment. Response was assessed by both serial alanine aminotransferase (ALT) levels and hepatitis C virus (HCV)-RNA measured by reverse transcribed polymerase chain reaction (RT-PCR) method. Before treatment, serum levels of HCV-RNA were measured quantitatively by second-generation branched-DNA assay and the HCV genotype was determined by RT-PCR. Serum HGV-RNA, a marker of infection with the hepatitis G virus, was also measured by RT-PCR. Normalization of ALT was sustained end serum HCV-RNA was cleared in 6 of 45 treated patients, compared with none of the 50 untreated controls (13% v 0% P <.01). Low pretreatment viremia was the only feature that was associated with an increased likelihood of sustained response (P <.01). This study shows that multitransfused hemophiliacs with chronic hepatitis C not coinfected with HIV-1 respond at low rates to prolonged interferon therapy.

Original languageEnglish
Pages (from-to)3529-3533
Number of pages5
JournalBlood
Volume89
Issue number10
Publication statusPublished - May 15 1997

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this